MBS funding for genome-wide microarray testing (GWMA) has been recommended by MSAC for people with multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL). The positive outcome recognises the advantages of GWMA for patients with haematological cancers including returning results faster and detecting more genetic variations than karyotyping. “For MM, MSAC supported the creation of a ...
Genome-wide microarray for MM and CLL coming to a lab near you
By Mardi Chapman
21 Apr 2020